Rovi Remains ‘Bullish’ On Enoxaparin Biosimilar With Much Room To Grow
Spanish Player Has 26% Market Share And Believes It Can Go Much Higher
Spain’s Laboratorios Farmaceuticos Rovi has set out why it remains confident in its prospects for its Becat (enoxaparin) biosimilar to Sanofi’s Lovenox/Clexane while providing an update for the firm’s Doria once-a-month injectable formulation of risperidone.
You may also be interested in...
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.
Introducing its Enoxaparin Becat biosimilar in both Spain and France during September this year – in the latter market through partner Biogaran – enabled Laboratorios Farmacéuticos Rovi to report turnover from the low molecular weight heparin (LMWH) of €7.8 million (US$8.9 million) in the third quarter, and €16.7 million in the first nine months, of this year. The Spanish firm has also just rolled out Becat in Austria and Latvia.